New insights into chemistry and anti-infective potential of triazole scaffold

Current Medicinal Chemistry

Volumn 18, Issue 21, 2011, Pages 3265-3297

  Kharb, R ^a   Yar, M Shahar ^b   Sharma, P C ^c  

^a CT Group of Institutions   (India)

^b HAMDARD UNIVERSITY   (India)

^c KURUKSHETRA UNIVERSITY   (India)

Author keywords

1,2; 1,2,3 triazole; 4 triazole; Antibacterial; Antifungal; Antimalarial activity; Antimycobacterial; Antiviral

Indexed keywords

1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (1H TETRAZOL 5 YL)ETHYL] 1H BENZO[D][1,2,3]TRIAZOLE; 1,2,3 TRIAZOLE DERIVATIVE; 1,2,4 TRIAZOLE DERIVATIVE; 1,5 DIPHENYL 1,2,3 TRIAZOLE; 1,5 DIPHENYL 1,2,4 TRIAZOLE; 3 (2,4 DICHLORO 5 FLUOROPHENYL) 4H 1,2,4 TRIAZOLE 3 THIOL; 3 (3' PYRIDYL) 1,2,4 TRIAZOLE 5 THIOL; 3 [(4 ACETYLPHENYL) 5 (1H 1,2,3 TRIAZOL 1 YL)METHYL]OXAZOLIDIN 2 ONE; 3,5 DIPHENYL 1,2,4 TRIAZOLE; 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 4H 1,2,4 TRIAZOLE; 5 TRIAZOLYLETHYL OXAZOLIDINONE DERIVATIVE; ANTIFUNGAL AGENT; CEFMATILEN; FLUCONAZOLE; FOSFLUCONAZOLE; HEXACONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; OXAZOLIDINONE DERIVATIVE; POSACONAZOLE; RADEZOLID; RAVUCONAZOLE; RIBAVIRIN; TARIBAVIRIN; TERCONAZOLE; TRIAZOLE DERIVATIVE; TRIAZOLO[4,3 A]QUINAZOLIN 7 ONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANDIDIASIS; CHEMICAL REACTION; CRYSTAL STRUCTURE; DRUG DECOMPOSITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROPHILICITY; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFLUENZA; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOPHILICITY; PNEUMONIA; SUBSTITUTION REACTION; TUBERCULOSIS; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; FUNGI; HUMANS; MODELS, MOLECULAR; MYCOSES; TRIAZOLES; VIRUS DISEASES; VIRUSES;

EID: 79959995244     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796391615     Document Type: Article

References (259)

1. Peleg, A. Y.; Hooper, D. C. Hospital-acquired infections due to Gramnegative bacteria. N. Engl. J. Med., 2010, 362, 1804-1813.
2. Vincent, J. L.; Rello. J.; Marshall, J. International study of the prevalence and outcomes of infection in intensive care units. J. A. M. A., 2009, 302, 2323-2329.
3. Filice, G. A.; Nyman, J. A.; Lexau, C. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect. Control Hosp. Epidemiol., 2010, 31, 365-373.
4. Cohen, M. L. Changing patterns of infectious diseases. Nature, 2000, 406, 762-767.
5. Paterson, D. L.; Yu, V. L. Extended-spectrum β-lactamases: a call for improved detection and control. Clin. Infect. Dis., 1999, 29, 1419-1422. (Pubitemid 30022734)
6. Rice, L. B.; Yao, J. D. C.; Klimm, K.; Eliopoulos, G. M.; Moellering, R. C. Efficacy of different β-lactams against an extended-spectrum β-lactamaseproducing Klebsiella pneumoniae strain in the rat intraabdominal abscess model. Antimicrob. Agents Chemother., 1991, 35, 1243-1244.
7. Alekshun, M. N.; Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell, 2007, 128, 1037-1050. (Pubitemid 46427883)
8. Vila, J.; Marti, S.; Sanchez-Cespedes, J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother., 2007, 59, 1210-1215. (Pubitemid 47073338)
9. Zhang, R.; Eggleston, K.; Rotimi, V.; Zeckhauser, RJ. Antibiotic resistance as a global threat: Evidence from China, Kuwait and the United States. Globalization and Health, 2006, 2, 1-14.
10. Davies, J. Bacteria on the rampage. Nature, 1996, 383, 219-220. (Pubitemid 26317657)
11. Field, H. J.; Coen, D. M. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J. Virol., 1986, 60, 286-289. (Pubitemid 16003171)
12. Muder, R. R.; Brennen, C.; Wagener, M. M. Temporal shifts in traits of Vibrio cholerae strains isolated from hospitalized patients in Calcutta: a 3-year (1993-1995) analysis. J. Clin. Microbiol., 1996, 34, 2537-2543.
13. Bisognano, C. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother., 1997, 41, 906-913. (Pubitemid 27194158)
14. Arason, V. A.; Kristinsson, K. G. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. B. M. J., 1996, 313, 387-391. (Pubitemid 26289973)
15. Seppala, H.; Klaukka, T. N. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group: A streptococci in Finland. Finnish Study Group for antimicrobial resistance. N. Engl. J. Med., 1997, 337, 441-446. (Pubitemid 27333044)
16. Levy, S. B.; Fitzgerald, G. B.; Macone, A. B. Spread of antibiotic-resistant plasmids from chicken to chicken and from chicken to man. Nature, 1976, 260, 40-42.
17. Levy, S. B.; Fitzgerald, G. B.; Macone, A. B. Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. N Engl. J. Med., 1976, 295, 583-588.
18. Witte, W. Selective pressure by antibiotic use in livestock. Int. J. Antimicrob. Agents, 2000, 16, 19-24.
19. Breathnach, A. S.; Ruiter, A.; Holdsworth, G. M. An outbreak of multi-drugresistant tuberculosis in a London teaching hospital. J. Hosp. Infect. 1998, 39, 111-117. (Pubitemid 28291227)
20. Hannan, M. M.; Azadian, B. S.; Gazzard, B. G. Hospital infection control in an era of HIV infection and multi-drug resistant tuberculosis. J. Hosp. Infect., 2000, 44, 5-11. (Pubitemid 30074329)
21. Martin, M. A. Methicillin-resistant Staphylococcus aureus: the persistent resistant nosocomial pathogen. Curr Clin. Top. Infect. Dis, 1994, 14, 170-191.
22. Wang, F.; Zhu, D. Surveillance of bacterial resistance in Shanghai. J. Infect. Chemother., 2002, 2, 1-9.
23. Cox, R. A.; Conquest, C.; Malaghan, C. A major outbreak of methicillinresistant Staphylococcus aureus caused by new phage-type (EMRSA-16). J. Hosp. Infect., 1995, 29, 87-106.
24. Astagneau, P. Cost of antimicrobial treatment for nosocomial infections based on a french prevalence survey. J. Hosp. Infect., 1999, 42, 303-312. (Pubitemid 29401518)
25. Haley, R. W.; Morgan, W. M.; Culver, D. H. Update from the SENIC project on hospital infection control: Recent progress and opportunities under prospective payment. Am. J. Infect. Control, 1985, 13, 97-108.
26. Duckworth, G. J. Diagnosis and management of methicillin resistant Staphylococcus aureus infection. B. M. J., 1993, 307, 1049-1052. (Pubitemid 23308313)
27. Richards, M. J.; Edwards, J. R.; Culver, D. H.; Gaynes, R. P. Nosocomial infections in medical intensive care units in the United States. Crit. Care Med., 1999, 27, 887-892. (Pubitemid 29266004)
28. Wiener, J.; Quinn, J. P.; Bradford, P. A.; Goering, R. V.; Nathan, C.; Bush, K.; Weinstein, R. A. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. J. A. M. A., 1999, 281, 517-523. (Pubitemid 29081304)
29. Thomson, K. S.; Prevan, A. M.; Sanders, C. C. Novel plasmid-mediated β-lactamases in enterobacteriaceae: emerging problems for new β-lactam antibiotics. Curr. Clin. Topics. Infect. Dis., 1996, 16, 151-163.
30. Gold, H. S.; Moellering, R. C. Antimicrobial-drug resistance. N. Engl. J. Med., 1996, 335, 1445-1452.
31. Karas, J. A.; Pillay, D. G.; Muckart, D.; Sturm, A. W. Treatment failure due to extended-spectrum β-lactamase. J. Antimicrob. Chemother., 1996, 37, 203-204. (Pubitemid 26123158)
32. Bonafede, M.; Rice, L. B. Emerging antibiotic resistance. J. Lab. Clin. Med., 1997, 130, 558-566. (Pubitemid 28029224)
33. Tenover, F. C.; Hughes, J. M. The challenges of emerging infectious diseases. J. A. M. A., 1996, 275, 300-304.
34. Leclercq, R.; Courvalin, P. Resistance to glycopeptides in enterococci. Clin. Infect. Dis., 1997, 24, 545-554.
35. Brown, T.; Charlier, P.; Herman, R.; Schofield, C. J.; Sauvage, E. Structural basis for the interaction of lactivicins with serine β-lactamases. J. Med. Chem., 2010, 53, 5890-5894.
36. Kumarasamy, K. K.; Toleman, M. A.; Walsh, T. R. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis., 2010, 10, 597-602.
37. Spellberg, B.; Guidos, R.; Gilbert, D. The epidemic of antibiotic-resistant infections: A call to action for the medical community from infectious disease society of America. Clin. Infect. Dis., 2008, 46, 155-164. (Pubitemid 351269151)
38. Charani, E.; Cooke, J.; Holmes, A. Antibiotic stewardship programmeswhat's missing? J. Antimicrob. Chemother., 2010, 65, 2275-2277.
39. Nalini, G. K Self-medication among allopathic medical doctors in karnatka, India. B. J. M. P., 2010, 3, 325-328.
40. Trias, J.; Gordon, E. M. Innovative approaches to novel antibacterial drug discovery. Curr. Opin. Biotechnol., 1997, 8, 757-762. (Pubitemid 27517254)
41. Greer, J.; Erickson, J. W.; Baldwin, J. J.; Varney, M. D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem., 1994, 37, 1035-1054. (Pubitemid 24145364)
42. Tan, D. S.; Foley, M. A.; Shair, M. D.; Schreiber, S. L. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J. Am. Chem. Soc., 1998, 120, 8565-8566. (Pubitemid 28420500)
43. Ichikawa, J. K.; Norris, A.; Bangera, M. G. Interaction of Pseudomonas aeruginosa with epithelial cells. Proc. Natl. Acad. Sci., 2000, 97, 9659-9664.
44. Wilson, M.; Risi, J. D.; Kristensen, H. H. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad. Sci., 1999, 96, 12833-12838. (Pubitemid 29513588)
45. Kavallaris, M.; Marshall, G. M. Proteomics and disease: opportunities and challenges. M. J. A., 2005, 182, 575-579. (Pubitemid 40823476)
46. Liu, B.; Pop, M. Antibiotic resistance genes database. Nucleic Acids Research, 2009, 37, 443-447.
47. Haney, S. A.; Alksne, L. E.; Dunman, P. M. Genomics in anti-infective drug discovery: getting to endgame. Curr. Pharm. Des., 2002, 8, 1099-1118. (Pubitemid 34594245)
48. Schmidt, F. R. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials. Appl. Microbiol. Biotechnol., 2004, 63, 335-343. (Pubitemid 38134770)
49. Bhattacharyya, B. K.; Sen, S. K. Antibiotics business: A glimpse. Indian J. Biotechnol., 2006, 5, 471-476. (Pubitemid 44862454)
50. Berdy, J. Microbial secondary metabolites play important roles in medicine: Prospects for discovery of new drugs. Prospect. Biol. Med., 1995, 40, 364-394.
51. Goodman, M. Market watch: Sales trends by therapeutic area. Nature Rev. Drug Discov., 2009, 8, 689-690.
52. Hamad, B. The antibiotics market. Nature Rev. Drug Discov., 2010, 9, 675-676.
53. Rosenthal, J. Upcoming market catalysts in the first quarter of 2010. Nature Rev. Drug Discov., 2010, 9, 11-12.
54. Nurhan, G.; Mevlut, S.; Neslihan, D. Synthesis and antimicrobial activities of some new 1, 2, 4-triazole derivatives. Turk. J. Chem., 2007, 31, 335-348.
55. Dabholkar, V. V.; Ansari, F. Y. Synthesis and biological studies of bis (thiadiazole/triazole) by sonication. Acta Pol. Pharm. Drug Res., 2008, 65, 521-526.
56. Edwards, J. E.; Bodey, G. P.; Bowden, R. A.; Buchner, T.; Pauw, B. E.; Filler, S. G.; Ghannoum, M. A.; Glauser, M.; Herbrecht, R.; Kauffman, C. A. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis., 1997, 25, 43-59.
57. White, T. C.; Marr, K. A.; Bowden, R. A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev., 1998, 11, 382-402. (Pubitemid 28197359)
58. Jarvis, W. R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis., 1995, 20, 1526-1530.
59. Edmond, M. B.; Wallace, S. E.; McClish, D. K.; Pfaller, M. A.; Jones, R. N.; Wenzel, R. P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis., 1999, 29, 239-244. (Pubitemid 29380177)
60. Hooshdaran, M. Z.; Barker, K. S.; Hilliard, G. M. Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents. Chemother., 2004, 48, 2733-2735. (Pubitemid 38823454)
61. Sanghvi, Y. S. Bhattacharya, B. K. Kini, G. D. Matsumoyo, S. S. Larson, S. B. Jolley, W. B.; Robins, R. K.; Revankar, G. R. Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin. J. Med. Chem., 1990, 33, 336-344. (Pubitemid 20038214)
62. Chen, M. D.; Lu, S. J.; Yuag, G. P.; Yang, S. Y.; Du, X. L. Synthesis and antimicrobial activity of some heterocyclic beta-enamino ester derivatives with 1, 2, 3-triazole. Heterocyclic. Comm., 2000, 6, 421-426.
63. Sherement, E. A.; Tomanov, R. I.; Trukhin, E. V.; Berestovitskaya, V. M. Synthesis of 4-aryl-5-nitro-1, 2, 3-triazoles. Russ. J. Org. Chem., 2004, 40, 594-595.
64. Hafez, H. N.; Abbas, H. A.; El-Gazzar, A. R. Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo-and 2-pyrazolyl-pyrido[2, 3-d]-pyrimidines. Acta Pharm., 2008, 58, 359-378.
65. Banu, K. M.; Dinaker, A.; Ananthnarayan, C. Synthesis, characterization of antimicrobial studies and pharmacological screening of some substituted 1, 2, 3-triazoles. Indian. J. Pharm. Sci., 1999, 61, 202-205.
66. Guan, L. P.; Jin, Q. H.; Tian, G. R.; Chai, K. Y.; Quan, Z. S. Synthesis of some quinoline-2 (1H)-one and 1, 2, 4-triazolo[4, 3-a]quinoline derivatives as potent anticonvulsants. J. Pharm. Sci., 2007, 10, 254-262.
67. Passannanti, A.; Diana, P.; Barraja, P.; Mingooia, F.; Lauria, A.; Cirrincine, G. Pyrrolo[2, 3-d][1, 2, 3]triazoles as potential antineoplastic agents. Heterocycles, 1998, 48, 1229-1235. (Pubitemid 128657650)
68. Manfredini, S.; Vicentini, C. B.; Manfrini, M.; Bianchi, N.; Rustigliano, C.; Mischiati, C.; Gambari, R. Pyrazolo-triazoles as light DNA cleaving agents. Bioorg. Med. Chem., 2000, 8, 2343-2346. (Pubitemid 30642758)
69. Duran, A.; Dogan, H. N.; Rollas, H. Synthesis and preliminary anticancer activity of new 1, 4-Dihydro-3-(3-hydroxy-2-naphthyl)-4-substituted-5H-1, 2, 4-triazoline-5-thiones. Farmaco, 2002, 57, 559-564. (Pubitemid 34765748)
70. Kumar, V.; Sharma, A.; Sharma, P. C. Synthesis of some novel 2, 5-disubstituted thiazolidinones from a long chain fatty acid as possible antiinflammatory, analgesic and hydrogen peroxide scavenging agents. J. Enzyme Inhib. Med. Chem., 2011, 26, 198-203.
71. th ed.; Pergamon Press: Oxford, 1979, pp. 357.
72. rd ed.; Pearson Education India: Singapore, 2005, pp. 298-307.
73. th ed.; John Wiley & Sons Inc. Publication: New Jersy, 2008.; pp. 103-109.
74. Araki, S.; Hirose, S.; Konishi, Y.; Nogura, M.; Hirashita, T. Synthesis of 3-(phenylazo)-1, 2, 4-triazoles by a nucleophilic reaction of primary amines with 5-chloro-2, 3-diphenyltetrazolium salt via mesoionic 2, 3-diphenyltetrazolium-5-aminides. Beilstein J. Org. Chem., 2009, 5, 1-6.
75. Mali, R. K.; Somani, R. R.; Toraskar, M. P.; Mali, K. K.; Naik, P. P.; Shirodkar, P. Y. Synthesis of some antifungal and anti-tubercular 1, 2, 4-triazole analogues. Int. J. Chem. Tech. Res., 2009, 1, 168-173.
76. George, V.; Mitra, A.; Sukumaran, K. B. Thermal and photochemical transformations of hetero-1, 3, 5-hexatrienes into five-membered ring - Possible pericyclic reactions. Angew. Chem. Int. Ed. Engl., 1980, 19, 973-983. (Pubitemid 11470052)
77. Lia, P.; Wang, L. One-Pot Synthesis of 1, 2, 3-triazoles from benzyl and alkyl halides, sodium azide and alkynes in water under transition-metal-catalyst free reaction conditions. Lett. Org. Chem., 2007, 4, 23-26.
78. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed., 2001, 40, 2004-2021.
79. Veverkova, E.; Toma, S. Microwave-assisted 1, 3-dipolar cycloaddition synthesis of substituted 9-(1, 2, 3-triazol-1-yl) acridines. Chem. Pap., 2005, 59, 350-353. (Pubitemid 43036107)
80. nd ed.; Wiley-VCH & Company: Deutschland, 2003, pp. 200-211.
81. Vereschagin, L. I.; Pokatilov, F. A.; Kizhnyaev, V. N. Synthesis and properties of nitro-1, 2, 3-triazoles. Chem. Heterocycl. Compd., 2008, 44, 1-19.
82. Gilchrist, T. L.; Gymer, G. E. Advances in Heterocyclic Chemistry, Elsevier Inc. Publication: Amsterdam, 1974, pp. 33-85.
83. th ed.; Pearson Education Limited: London, 2006, pp. 30-76.
84. th ed.; John Wiley & Sons Inc. Publication: New Jersy, 1998, pp. 109.
85. st ed.; Blackwell Publishing Limited: Canada, 2003, pp. 203-236.
86. Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogel's Textbook of Practical Organic Chemistry, 5 ed.; Longman Group UK Limited Publication: England, 1989, pp. 316-361.
87. nd ed.; John Wiley & Sons Inc. Publication: New Jersy, 2004, pp. 164-179.
88. Kallury, M. R.; Nath, G. S.; Srinivasan, V. R Mass spectra of 1, 2, 4-triazoles: A novel skeletal rearrangement. Aus. J. Chem., 1975, 28, 2089-2091.
89. Heitke, B. T.; McCarty, G. Mass spectra of C-amino and C-azido-1, 2, 4-triazoles. Can. J. Chem., 1974, 52, 2861-2865.
90. Chauhan, J. Comparative X-Ray structure analysis of systemic fungicides β-4 (-Chlorophenoxy)-α-(1, 1dimethylethyl)) 1H-1, 2, 4-triazole-1-ethanol and 1-(4 Chlorophenoxy) 3, 3-dimethyl-1-H (1, 2, 4-triazole-1-Y-1) 2-butanone. J. Appl. Sci. Res., 2008, 4, 166-170.
91. Larina, L. Nitroazoles: Synthesis, Structure and Applications, 1st ed.; Springer Publications: New York, 2009, pp. 176-177.
92. Brumfitt, W.; Hamilton-Muller, J. M. T. The challenges of methicillinresistant Staphylococcus aureus. J. Drug. Exp. Clin. Res., 1994, 20, 215-224.
93. Neu, H. C. The crisis in the antibiotic resistance. Science, 1992, 257, 1064-1074.
94. Jana, C.; Julius, S. Resistance in fluconazole-resistant candida albicans, isolates from vaginal candidiasis. Int. J. Antimicrob. Agents, 2006, 27, 403-408.
95. Bagihallia, G. B.; Patila, S. A.; Badamib, P. S. Synthesis, physicochemical investigation and biological studies of zinc (II) complexes with 1, 2, 4-triazole schiff bases. J. Iran. Chem. Soc., 2009, 6, 259-270.
96. Holmes, C. B.; Losina, E.; Walensky, RP. Review of human immunodeficiency virus type I-related opportunistic infections in sub-Saharan Africa. Clin. Infect. Dis., 2003, 36, 652-662. (Pubitemid 36259573)
97. Fuloria, N. K.; Singh, V.; Shaharyar, M.; Ali, M. Synthesis, characterization and antimicrobial evaluation of novel imines and thiazolidinones. Acta Pol. Pharm. Drug Res., 2009, 66, 141-146.
98. Fuloria, N. K.; Singh, V.; Shaharyar, M.; Ali, M. Synthesis and antimicrobial evaluation of some new oxadiazoles derived from phenylpropionohydrazides. Molecules, 2009, 14, 1898-1903.
99. Husain, A.; Shaharyar, M. Synthesis and antibacterial activity of epoxides derived from chalcones. Asian J. Chem., 2005, 17, 624-626. (Pubitemid 40386686)
100. Flemming, A. Antibacterials: New strategy to target Pseudomonas. Nat. Rev. Drug Discov., 2010, 9, 270-271.
101. Sharma, PC.; Jain, A.; Jain, S.; Pahwa, R.; Shaharyar, M. Ciprofloxacin: Review on developments in synthetic, analytical and medicinal aspects. J. Enz. Inhib. Med. Chem., 2010, 25, 577-589.
102. Kharb, R.; Sharma, PC.; Shaharyar, M. Pharmacological significance of triazole scaffold. J. Enzyme Inhib. Med. Chem., 2011, 26, 1-21.
103. Jones, D. A guiding hand for antibiotics. Nat. Rev. Drug Discov., 2011, 10, 161-162.
104. Choi, S.; Isaacs, A.; Clements, D.; Liu, D.; Kim, H.; Scott, R. W.; Winkler, J. D.; DeGrado, W. F. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 6968-6973.
105. Sharma, P. C.; Sharma, S. V.; Badami, S.; Sharma, A.; Suresh, B. Microwaveinduced efficient synthesis and anti-fungal evaluation of some n-phenyl-3-(substituted phenyl) propenamides. Indian J. Pharm. Edu. Res., 2007, 41, 140-145.
106. Sharma, PC.; Sharma, S. V.; Suresh, B. CoMFA (3D-QSAR) studies on certain 3-aryl-4-[α-(1H-imidazol-1-yl) aryl methyl] pyrroles as Potent anti-Candida Indian J. Pharm. Sci., 2008, 70, 154-158.
107. Sharma, P. C.; Jain, A.; Jain, S. Fluoroquinolone antibacterials: An update on chemistry, microbiology and therapeutic prospects. Acta Pol. Pharm. Drug Res., 2009, 66, 587-604.
108. Chawla, R.; Arora, A.; Parameswaran, M. K.; Sharma, P. C.; Michael, S.; Ravi, T. K. Synthesis of novel 1, 3, 4-oxadiazole derivatives as potential antimicrobial agents. Acta Pol. Pharm. Drug Res., 2010, 67, 247-253.
109. Deep, A.; Jain, S.; Sharma, P. C.; Verma, P.; Kumar, M.; Dora, CP. Design and biological evaluation of biphenyl-4-carboxylic acid hydrazide hydrazone for antimicrobial activity. Acta Pol. Pharm. Drug Res., 2010, 67, 255-259.
110. Chawla, R.; Sahoo, U.; Arora, A.; Sharma, P. C.; Vijayaraj, R Microwave assisted synthesis of some novel 2-pyrazoline derivatives as possible antimicrobial agents. Acta Pol. Pharm. Drug Res., 2010, 67, 55-61.
111. Sharma, P. C.; Sharma. S. V.; Jain. S.; Singh. D.; Suresh, B. Synthesis of certain isoxazoline derivatives as possible anti-candida agents. Acta Pol. Pharm. Drug Res., 2009, 66, 101-104.
112. Santo, R. D.; Tafi, A.; Costi, R.; Botta, M.; Artico, M.; Corelli, F.; Forte, M.; Caporuscio, F.; Angiolella, L. N-Substituted Derivatives of 1-[(Aryl) (4-aryl-1 H-pyrrol-3-yl) methyl]-1 H-imidazole: Synthesis, anti-candida activity, and QSAR Studies. J. Med. Chem., 2005, 48, 5140-5153.
113. Sharma, P. C.; Sharma, O. P.; Vasudeva. N.; Mishra. D. N.; Singh, S. K. Anti-HIV substances of natural origin: an updated account. Nat. Prod. Rad., 2006, 5, 70-78.
114. Sharma, P. C.; Saneja, A.; Jain, S. Norfloxacin: A therapeutic review. Int. J. Chem. Sci., 2008, 6, 1702-1713.
115. Vicini, P.; Geronikaki, A.; Anastasia, K.; Incerti, M.; Zani, F. Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4- thiazolidinones. Bioorg. Med. Chem., 2006, 14, 3859-3864.
116. Yasemin, U.; Esra, D.; Kemal, S.; Mustafa, E. Synthesis and antimicrobial evaluation of novel di-triazoles and 4-arylidene amino 4, 5-dihydro-1 H-[1, 2, 4] triazole-5-one derivatives. Turk. J. Chem., 2008, 32, 441-455.
117. Stefanska, J.; Struga, M.; Tyski, S.; Dobosz, M. Antimicrobial activity of 2, 4-dihydro-[1, 2, 4]triazolo-3-one derivatives. Pol. J. Microbiol., 2008, 57, 179-182.
118. Sheehan, D. J.; Hitchcock, C. A.; Sibley, CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev., 1999, 12, 40-79. (Pubitemid 29055953)
119. Demir-Erol, D.; Calis, U.; Demirdamar, R.; Nulug, N.; Ertan, M. Synthesis and biological activities of some 3, 6-disubstituted-thiazolo[3, 2-b][1, 2, 4]triazoles. J. Pharm. Sci., 1995, 84, 462-465.
120. Phillips, O. A.; Udo, E. E.; Ali, A. A.; Samuel, S. M. Structure-antibacterial activity of arylcarbonyl-and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones. Eur. J. Med Chem., 2007, 42, 214-225.
121. Phillips, O. A.; Udo, E. E.; Samuel, S. M. Synthesis and structure-antibacterial activity of triazolyl oxazolidinones containing long chain acyl moiety. Eur. J. Med. Chem., 2008, 43, 1095-1104.
122. Phillips, O. A.; Udo, E. E.; Abdel-Hamid, M. E.; Varghese, R Synthesis and antibacterial activity of novel 5-(4-methyl-1 H-1, 2, 3-triazole) methyl oxazolidinones Eur. J. Med. Chem., 2009, 44, 3217-3227.
123. Pokrovskaya, V.; Belakhov, V.; Hainrichson, M.; Yaron, S.; Baasov, T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J. Med. Chem., 2009, 52, 2243-2254.
124. Almajan, G. L.; Barbuceanu, S. F.; Almajan, E. R.; Draghici, C.; Saramet, G. Synthesis, characterization and antibacterial activity of some triazole Mannich bases carrying diphenylsulfone moieties. Eur. J. Med. Chem., 2009, 44, 3083-3089.
125. Patil, B. S.; Krishnamurthy, G.; Bhojya Naik, H. S.; Latthe, P. R.; Ghate, M. Synthesis, characterization and antimicrobial studies of 2-(4-methoxyphenyl)-5-methyl-4-(2-arylsulfanyl-ethyl)-2, 4-dihydro-[1, 2, 4]triazolo-3-ones and their corresponding sulfones. Eur. J. Med. Chem., 2010, 45, 3329-3334.
126. Demaray, J. A.; Thuener, J. E.; Dawson, M. N.; Sucheck, S. J. Synthesis of triazole-oxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity. Bioorg. Med. Chem. Lett., 2008, 18, 4868-4871.
127. Al-Omar, M. A.; Al-Abdullah, E. S.; Shehata, I. A.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A. Synthesis, antimicrobial, and anti-inflammatory activities of novel 5-(1-adamantyl)-4-arylideneamino-3-mercapto-1, 2, 4-triazoles and related derivatives. Molecules, 2010, 15, 2526-2550.
128. Al-Omar, M. A. Synthesis and antimicrobial activity of new 5-(2-thienyl) - 1, 2, 4-triazoles and 5-(2-thienyl)-1, 3, 4-oxadiazoles and related derivatives. Molecules, 2010, 15, 502-514.
129. Pandey, S. K.; Singh, A.; Nizamuddin, A. Antimicrobial studies of some novel quinazolinones fused with[1, 2, 4]-triazole, [1, 2, 4]-triazine and[1, 2, 4, 5]-tetrazine rings. Eur. J. Med. Chem., 2009, 44, 1188-1197.
130. Karthikeyan, M. S. Synthesis, analgesic, anti-inflammatory and antimicrobial studies of 2, 4-dichloro-5-fluorophenyl containing thiazolotriazoles. Eur. J. Med. Chem., 2009, 44, 827-833.
131. Onkol, T.; Dogruer, D. S.; Uzun, L.; Adak, S.; Ozkan, S.; Sahin, M. F. Synthesis and antimicrobial activity of new 1, 2, 4-triazole and 1, 3, 4-thiadiazole derivatives. J. Enzyme Inhib. Med. Chem., 2008, 23, 277-284. (Pubitemid 351404849)
132. Vatmurge, N. S.; Hazra, B. G.; Pore, V. S.; Shirazi, F.; Chavan, P. S.; Deshpande, M. V. Synthesis and antimicrobial activity of β-lactam-bile acid conjugates linked via triazole. Bioorg. Med. Chem. Lett., 2008, 18, 2043-2047. (Pubitemid 351380871)
133. Guzeldemirci, N. U.; Kucukbasmaci, O. Synthesis and antimicrobial activity evaluation of new 1, 2, 4-triazoles and 1, 3, 4-thiadiazoles bearing imidazo[2, 1-b]thiazole moiety. Eur. J. Med. Chem., 2010, 45, 63-68.
134. Ezabadi, I. R.; Camoutsis, C.; Zoumpoulakis, P.; Geronikaki, A.; Sokovic, M. Glamocilija, J.; Ciric, A. Sulfonamide-1, 2, 4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies. Bioorg. Med. Chem., 2008, 16, 1150-1161. (Pubitemid 351193036)
135. Mani Chandrika, P.; Yakaiah, T.; Gayatri, G.; Kumar, P. K.; Narsaiah, B.; Murthy, U. S.; Rao RRA. Click chemistry: studies on the synthesis of novel fluorous tagged triazol-4-yl substituted quinazoline derivatives and their biological evaluation-theoretical and experimental validation. Eur. J. Med. Chem., 2010, 45, 78-84.
136. Pintilie, O.; Profire, L.; Sunel, V.; Popa, M.; Pui, A. Synthesis and antimicrobial activity of some new 1, 3, 4-thiadiazole and 1, 2, 4-triazole compounds having a D, L-methionine moiety. Molecules, 2007, 12, 103-113.
137. Salgin-Goksen, U.; Gokhan-Kelekci, N.; Goktas, O.; Koysal, Y.; Kilic, E.; Isik, S.; Aktay, G.; Ozalp, M. 1-acylthiosemicarbazides, 1, 2, 4-triazole-5 (4H)-thiones, 1, 3, 4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones: synthesis, analgesic-anti-inflammatory and antimicrobial activities. Bioorg. Med. Chem., 2007, 15, 5738-5751. (Pubitemid 47043477)
138. Sztanke, K.; Pasternak, K.; Sidor-Wojtowicz, A.; Truchlinska, J.; Jozwiak, K. Synthesis of imidazoline and imidazo[2, 1-c][1, 2, 4]triazole aryl derivatives containing the methylthio group as possible antibacterial agents. Bioorg. Med. Chem., 2006, 14, 3635-3642. (Pubitemid 44316607)
139. Sztanke, K.; Tuzimski, T.; Rzymowska, J.; Pasternak, K.; Kandefer-Szerszen, M. Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1, 2, 4-triazole derivatives. Eur. J. Med. Chem., 2008, 43, 404-419. (Pubitemid 351215604)
140. Fan, H.; Xu, G.; Chen, Y.; Jiang, Z.; Zhang, S.; Yang, Y.; Ji, R. Synthesis and antibacterial activity of oxazolidinones containing triazolyl group. Eur. J. Med. Chem., 2007, 42, 1137-1143. (Pubitemid 47081244)
141. Singh, K.; Singh, D. P.; Barwa, M. S.; Tyagi, P.; Mirza, Y. Antibacterial Co (II), Ni (II), Cu (II) and Zn (II) complexes of Schiff bases derived from fluorobenzaldehyde and triazoles. J. Enzyme Inhib. Med. Chem., 2006, 21, 557-562. (Pubitemid 44768465)
142. El-Hawash, S. A.; Habib, N. S.; Kassem, M. A. Synthesis of some new quinoxalines and 1, 2, 4-triazolo[4, 3-a]-quinoxalines for evaluation of in vitro antitumor and antimicrobial activities. Arch. Pharm., 2006, 339, 564-571. (Pubitemid 44638521)
143. Karakurt, A.; Aytemir, M. D.; Stables, J. P.; Ozalp, M.; Betul Kaynak, F.; Ozbey, S.; Dalkara, S. Synthesis of some oxime ether derivatives of 1-(2-naphthyl)-2-(1, 2, 4-triazol-1-yl) ethanone and their anticonvulsant and antimicrobial activities. Arch. Pharm., 2006, 339, 513-520. (Pubitemid 44534956)
144. Rajasekaran, A.; Murugesan, S.; Rajagopal, A. K. Antibacterial, antifungal and anticonvulsant evaluation of novel newly synthesized 1-[2-(1 H-tetrazol-5-yl) ethyl]-1 H-benzo[d][1, 2, 3]triazoles. Arch. Pharm. Res., 2006, 29, 535-540. (Pubitemid 44199352)
145. Khalil, N. S. Efficient synthesis, structure, and antimicrobial activity of some novel N-and S-|3-D-glucosides of 5-pyridin-3-yl-1, 2, 4-triazoles. Carbohydr. Res., 2006, 341, 2187-2199. (Pubitemid 44092681)
146. Holla, B. S.; Sarojini, B. K.; Rao, B. S.; Akberali, P. M.; Kumari, S. N.; Shetty, V. Synthesis of some halogen-containing 1, 2, 4-triazolo-1, 3, 4-thiadiazines and their antibacterial and anticancer screening studies-Part I. Farmaco, 2001, 56, 565-570. (Pubitemid 32727927)
147. Holla, B. S.; Shridhara, K.; Rao, B. S.; Poojary, K. N. Synthesis, characterization and antibacterial activities of some N-bridged heterocycles containing triazole, quinoline and nitrofuran moieties. Boll. Chim. Farm., 2002, 141, 105-109. (Pubitemid 34746891)
148. Holla, B. S.; Rao, B. S.; Sarojini, B. K.; Akberali, P. M.; Kumari, S. N. Synthesis and studies on some new fluorine containing triazolothiadiazines as possible antibacterial, antifungal and anticancer agents. Eur. J. Med. Chem., 2006, 41, 657-663. (Pubitemid 43792322)
149. Mohamed, B. G.; Hussein, M. A.; Abdel-Alim, A. A.; Hashem, M. Synthesis and antimicrobial activity of some new 1-alkyl-2-alkylthio-1, 2, 4-triazolobenzimidazole derivatives. Arch. Pharm. Res., 2006, 29, 26-33. (Pubitemid 43268419)
150. Pomarnacka, E.; Bednarski, P. J.; Reszka, P.; Dziemidowicz-Borys, E.; Bienczak, A.; Werel, W.; Hałasa, R Synthesis and biological activity of new 2-amino-8-chloro-5, 5-dioxo[1, 2, 4]triazolo[2, 3-b][1, 4, 2]benzodithiazines. Eur. J. Med. Chem., 2006, 41, 633-639.
151. Turan-Zitouni, G.; Kaplancikli, Z. A.; Yildiz, M. T.; Chevallet, P.; Kaya, D. Synthesis and antimicrobial activity of 4-phenyl/cyclohexyl-5-(1- phenoxyethyl)-3-[N-(2-thiazolyl) acetamido]thio-4H-1, 2, 4-triazole derivatives. Eur. J. Med. Chem., 2005, 40, 607-613. (Pubitemid 40732529)
152. Reck, F.; Zhou, F.; Girardot, M.; Kern, G.; Eyermann, C. J.; Hales, N. J.; Ramsay, RR.; Gravestock, M. B. Identification of 4-substituted 1, 2, 3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem., 2005, 48, 499-506. (Pubitemid 40139792)
153. Prakash, O.; Bhardwaj, V.; Kumar, R.; Tyagi, P.; Aneja, K. R Organoiodine (III) mediated synthesis of 3-aryl/hetryl-5, 7-dimethyl-1, 2, 4-triazolo[4, 3-a]pyrimidines as antibacterial agents. Eur. J. Med. Chem., 2004, 39, 1073-1077. (Pubitemid 39574938)
154. Nasr, M. N.; Gineinah, M. M.; El-Bendary, E. R. Synthesis and in vitro antibacterial evaluation of novel imidazo[2', 1':5, 1]-1, 2, 4-triazolo[4, 3-c]-quinazoline derivatives of 5-thioxo-1, 2, 4-triazole, 4-oxothiazolidine, and their open-chain counterparts. Arch. Pharm., 2003, 336, 560-566. (Pubitemid 38076211)
155. Papakonstantinou-Garoufalias, S.; Pouli, N.; Marakos, P.; Chytyroglou-Ladas, A. Synthesis antimicrobial and antifungal activity of some new 3 substituted derivatives of 4-(2, 4-dichlorophenyl)-5-adamantyl-1 H-1, 2, 4-triazole. Farmaco, 2002, 57, 973-977. (Pubitemid 35477625)
156. Chohan, Z. H.; Scozzafava, A.; Supuran, C. T. Unsymmetrical 1, 1'-disubstituted ferrocenes: synthesis of Co (ii), Cu (ii), Ni (ii) and Zn (ii) chelates of ferrocenyl-1-thiadiazolo-1'-tetrazole,-1-thiadiazolo-1'-triazole and-1-tetrazolo-1'-triazole with antimicrobial properties. J. Enzyme Inhib. Med. Chem., 17, 2002, 261-266. (Pubitemid 35175262)
157. Shafiee, A.; Sayadi, A.; Roozbahani, M. H.; Foroumadi, A.; Kamal, F. Synthesis and in vitro antimicrobial evaluation of 5-(1-methyl-5-nitro-2- imidazolyl)-4H-1, 2, 4-triazoles. Arch. Pharm., 2002, 335, 495-499. (Pubitemid 36125518)
158. Ulusoy, N.; Gursoy, A.; Otuk, G. Synthesis and antimicrobial activity of some 1, 2, 4-triazole-3-mercaptoacetic acid derivatives. Farmaco, 2001, 56, 947-952. (Pubitemid 34019224)
159. Ulusoy, N.; Ergenc, N.; Otuk, G.; Kiraz, M. Synthesis of some 4-(alkylidene/arylidene) amino-2, 4-dihydro-5-(2-thienyl)-3H-1, 2, 4-triazole-3-thiones tested for antimicrobial activity. Boll. Chim. Farm., 2001, 140, 417-421. (Pubitemid 34037387)
160. Baraldi, P. G.; Pavani, M. G.; Nunez Mdel, C.; Brigidi, P.; Vitali, B.; Gambari, R.; Romagnoli, R. Antimicrobial and antitumor activity of N-heteroimmine-1, 2, 3-dithiazoles and their transformation in triazolo-,
161. Bhat, A. R.; Bhat, G. V.; Shenoy, G. G. Synthesis and in-vitro antimicrobial activity of new 1, 2, 4-triazoles. J. Pharm. Pharmacol., 2001, 53, 267-272. (Pubitemid 32156523)
162. Ersan, S.; Nacak, S.; Berkem, R. Synthesis and antimicrobial activity of N-[(alpha-methyl) benzylidene]-(3-substituted-1, 2, 4-triazol-5-yl-thio) acetohydrazides. Farmaco, 1998, 53, 773-776. (Pubitemid 29171491)
163. Barreca, M. L.; Chimirri, A.; Luca, L. D.; Monforte, A. M.; Monforte, P.; Rao, A.; Zappala, M., Balzarini, J., Clercq, E. D., Pannecouque, C., Witvrouw, M. Discovery of 2, 3-diaryl-1, 3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett., 2001, 11, 1793-1796. (Pubitemid 32568322)
164. Kharb, R.; Shaharyar, M.; Sharma, P. C. Recent advances and future perspectives of triazole analogs as promising antiviral agents. Mini Rev. Med. Chem., 2011, 11, 84-96.
165. Ali, M. A.; Shaharyar M.; De Clercq, E. Synthesis of 5-(4-hydroxy-3- methylphenyl)-5-(substituted phenyl)-4, 5-dihydro-1H-1-pyrazolyl-4- pyridylmethanone derivatives with anti-viral activity. J. Enzyme Inhib. Med. Chem., 2007, 22, 702-708. (Pubitemid 350215073)
166. Sepkowitz, K. A. AIDS-the first 20 years. N. Engl. J. Med., 2001, 344, 1764-1772.
167. Weiss, R. A. How does HIV cause AIDS? Science, 1993, 260, 1273-1279. (Pubitemid 23231970)
168. Kakkar, S.; Mohanraj, K.; Sharma, P. C. Simple and rapid RP-HPLC method to determine the purity of the anti-retroviral drug lamivudine. Lat. Am. J. Pharm., 2010, 29, 1075-1081.
169. Guss, D. A. The acquired immune deficiency syndrome: an overview for the emergency physician. J. Emerg. Med., 1994, 12, 375-384. (Pubitemid 24166681)
170. Ali, M. A.; Shaharyar, M.; Siddiqui, A. A.; Sriram, D.; Yogeeswari, P.; De Clercq, E. Synthesis and Anti-HIV of N1-nicotinoyl-3-(4'-hydroxy-3'-methyl phenyl)-5-[(sub) phenyl]-2-pyrazolines. Acta Pol. Pharm. Drug Res., 2007, 63, 423-428. (Pubitemid 351360397)
171. Pilot, P.; Bartos, M.; Ghys, P. D.; Walker, N.; Schwartlander, B. The global impact of HIV/AIDS. Nature, 2001, 401, 968-973. (Pubitemid 32335847)
172. Guss, D. A. The acquired immune deficiency syndrome: an overview for the emergency physician, Part 2. J. Emerg. Med., 1994, 12, 491-497. (Pubitemid 24243048)
173. Feldman, C. Pneumonia associated with HIV infection. Curr. Opin. Infect. Dis., 2005, 18, 165-170. (Pubitemid 40380217)
174. Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; Clercq, E. D.; Monforte, A. M.; Monforte, P.; Pannecouque, C.; Zappala, M. 2-(2, 6-dihalophenyl)-3-(pyrimidin-2-yl)-1, 3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res., 2004, 63, 79-84. (Pubitemid 39061772)
175. Rao, A.; Carbone, A.; Chimirri, A.; Clercq, E. D.; Monforte, A. M.; Monforte, P.; Pannecouque, C.; Zappala, M. Synthesis and anti-HIV activity of 2, 3-diaryl-1, 3-thiazolidin-4-ones. Farmaco, 2003, 58, 115-120. (Pubitemid 36197647)
176. Dybul, M.; Fauci, A. S.; Bartlett, J. G.; Kaplan, J. E.; Pau, A. K. Panel on clinical practices for treatment of HIV-guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med., 2002, 137, 381-433. (Pubitemid 34982041)
177. Palella, F. J.; Delaney, K. M.; Moorman, A. C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection-HIV outpatient study investigators. N. Engl. J. Med., 1998, 338, 853-860. (Pubitemid 28135961)
178. Kallings, L. O. The first postmodern pandemic: 25 years of HIV/AIDS. J. Intern. Med., 2008, 263, 218-243. (Pubitemid 351207350)
179. Wang, Z.; Wu, B.; Kuhen, K. L.; Bursulaya, B.; Nguyen, T. N.; Nguyen D. G.; He Y. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4174-4177.
180. Johns, B. A.; Weatherhead, J. G.; Allen, S. H.; Thompson, J. B.; Garvey, E. P.; Foster, S. A.; Jeffrey, J. L.; Miller, W. H. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorg. Med. Chem. Lett., 2009, 19, 1802-1806.
181. Wan, J.; Xia, Y.; Liu, Y.; Wang, M.; Rocchi, P.; Yao, J.; Qu, F.; Neyts, J.; Iovanna, J. L.; Peng, L. Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity. J. Med. Chem., 2009, 52, 1144-1155.
182. Chittepu, P.; Sirivolu, V. R.; Seela, F. Nucleosides and oligonucleotides containing 1, 2, 3-triazole residues with nucleobase tethers: synthesis via the azide-alkyne click reaction. Bioorg. Med. Chem., 2008, 16, 8427-8439.
183. Al-Soud, Y. A.; Al-Dweri, M. N.; Al-Masoudi, N. A. Synthesis, antitumor and antiviral properties of some 1, 2, 4-triazole derivatives. Farmaco, 2004, 59, 775-783. (Pubitemid 39341178)
184. Al-Soud, Y. A.; Al-Masoudi, N. A.; Loddo, R.; La Colla, P. In-vitro anti-HIV and antitumor activity of new 3, 6-disubstituted[1, 2, 4]triazolo[3, 4-b][1, 3, 4]thiadiazoles and thiadiazine analogues. Arch. Pharm., 2008, 341, 365-369.
185. Zhu, R.; Wang, M.; Xia, Y.; Qu, F.; Neyts, J.; Peng, L. Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication. Bioorg. Med. Chem. Lett., 2008, 18, 3321-3327. (Pubitemid 351721004)
186. Abdel-Aal, M. T.; El-Sayed, W. A.; El-Kosy, S. M.; El-Ashry, S. H. Synthesis and antiviral evaluation of novel 5-(N-aryl-aminomethyl-1, 3, 4-oxadiazol-2-yl) hydrazines and their sugars, 1, 2, 4-triazoles, tetrazoles and pyrazolyl derivatives. Arch. Pharm., 2008, 341, 307-313.
187. Chung, D. H.; Kumarapperuma, S. C.; Sun, Y.; Li, Q.; Chu, Y. K.; Arterburn, J. B.; Parker, W. B.; Smith, J.; Spik, K.; Ramanathan, H. N.; Schmaljohn, C. S.; Jonsson, C. B. Synthesis of 1-β-D-ribofuranosyl-3- ethynyl-[1, 2, 4]triazole and its in vitro and in vivo efficacy against Hanta virus. Antiviral Res., 2008, 79, 19-27.
188. Shamroukh, A. H.; Ali, M. A. Anti-HAV activity of some newly synthesized triazolo[4, 3-b]pyridazines. Arch. Pharm., 2008, 341, 223-230.
189. Vivet-Boudou, V.; Paillart, J. C.; Burger, A.; Marquet, R. In search of new inhibitors of HIV-1 replication: synthesis and study of 1-(2'-Deoxy-β- D-Ribofuranosyl)-1, 2, 4-triazole-3-carboxamide as a selective viral mutagenic agent. Nucleosides Nucleotides Nucleic Acids, 2007, 26, 743-746. (Pubitemid 350239213)
190. Li, J.; Zheng, M.; Tang, W.; He, P. L.; Zhu, W.; Li, T.; Zuo, J. P.; Liu, H.; Jiang, H. Synthesis of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities. Bioorg. Med. Chem. Lett., 2006, 16, 5009-5013. (Pubitemid 44262496)
191. De La Rosa, M.; Kim, H. W.; Gunic, E.; Jenket, C.; Boyle, U.; Koh, Y. H.; Korboukh, I.; Allan, M.; Zhang, W.; Chen, H.; Xu, W.; Nilar, S.; Yao, N.; Hamatake, R.; Lang, S. A.; Hong, Z.; Zhang, Z.; Girardet, J. L. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2006, 16, 4444-4449. (Pubitemid 44094093)
192. Van Aerschot, A.; Schepers, G.; Busson, R.; Rozenski, J.; Neyts, J.; De Clercq, E.; Herdewijn, P. Ribavirin derivatives with a hexitol moiety: synthesis and antiviral evaluation. Antivir. Chem. Chemother., 2003, 14, 23-30. (Pubitemid 36565909)
193. Zhang, Y.; Jamaluddin, M.; Wang, S.; Tian, B.; Garofalo, R. P.; Casola, A.; Brasier, A. R. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virusinfected epithelial cells. J. Virol., 2003, 77, 5933-5947. (Pubitemid 36538985)
194. Abdel-Hafez, A. A.; Elsherief, H. A.; Jo, M.; Kurokawa, M.; Shiraki, K.; Kawahata, T.; Otake, T.; Nakamura, N.; Hattori, M. Synthesis and evaluation of anti-HIV-1 and anti-HSV-1 activities of 4H-[1, 2, 4]-triazolo[1, 5-a]pyrimidin-5-one derivatives. Arzneimittelforschung., 2002, 52, 833-839. (Pubitemid 35398734)
195. Ali, M. A.; Shaharyar, M. Discovery of novel phenoxyacetic acid derivatives as antimycobacterial agents. Bioorg. Med. Chem., 2007, 15, 1896-1902. (Pubitemid 46176639)
196. Ali, M. A.; Shaharyar, M. Oxadiazole mannich bases: Synthesis and antimycobacterial activity. Bioorg. Med. Chem. Lett., 2007, 17, 3314-3316. (Pubitemid 46819034)
197. Shaharyar, M.; Siddiqui, A. A.; Mohamed, A. A.; Sriram, D.; Yogeeswari. P. Synthesis and in vitro antimycobacterial activity of N1-nicotinoyl-3-(4- hydroxy-3-methylphenyl)-5-[(sub) phenyl]-2-pyrazolines. Bioorg. Med. Chem. Lett., 2006, 16, 3947-3949. (Pubitemid 43903222)
198. Kucukguzel, G.; Kocatepe, A.; De Clercq, E.; Sahin, F.; Gulluce, M. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur. J. Med. Chem., 2006, 41, 353-359.
199. Ali, M. A.; Shaharyar, M. Synthesis of novel substituted pyrazolyl-2-toluidinomethanethione as potential antitubercular agents. Acta Pol. Pharm. Drug Res., 2007, 64, 139-146. (Pubitemid 351356902)
200. Ali, M. A.; Shaharyar, M. Antitubercular activity of novel substituted 4, 5-dihydro-1 H-1-pyrazolylmethanethiones. J. Enzyme Inhib. Med. Chem., 2007, 22, 183-189 (Pubitemid 46592507)
201. th ed.; Saunders Elsevier Publication, 2007, pp. 516-522.
202. Shaharyar, M.; Siddiqui, A. A.; Ali. M. A. Synthesis and evaluation of phenoxy acetic acid derivatives as a anti-mycobactrial agents. Bioorg. Med. Chem. Lett., 2006, 16, 4571-4574. (Pubitemid 44094073)
203. Ali, M. A.; Shaharyar, M.; Sriram, D.; Yogeeswari. P. Synthesis and antimicrobial activity of 3-(4'-hydroxy-3'-methylphenyl)-5-[(substuted) phenyl]-4, 5-dihydro-1 H-1-pyrazolyl-4-pyridylmethanone derivatives. Acta Pol. Pharm. Drug Res., 2006, 63, 491-496. (Pubitemid 351360452)
204. Shaharyar, M.; Siddiqui, A. A.; Ali, M. A. Synthesis and antimycobacterial activity of novel heterocycles. Serbian Journal of Chemical Society, 2007, 72, 5-11.
205. Ali, M. A.; Shaharyar, M.; Siddiqui, A. A. Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives. Eur. J. Med. Chem., 2006, 42, 268-275.
206. Shaharyar, M.; Siddiqui, A. A.; Ali, M. A. Synthesis and anti-tuberculostatic activity of novel 1, 3, 4-oxadiazole derivatives. J. Chinese. Chem. Soc., 2007, 54, 5-8.
207. Ballel, L.; Field, R. A.; Duncan, K.; Young, R. New small molecule synthetic antimycobacterials. Antimicrob. Agents Chemother., 2005, 49, 2153-2163. (Pubitemid 40734441)
208. Ali, M. A.; Shaharyar M.; Siddiqui, A. A.; Husain, A.; Abdullah, M. Synthesis and in-vitro antimycobacterial activity of amino-5-[(substituted) phenyl]-3-(4-hydroxy-3-methylphenyl)-4, 5-dihydro-1 H-1-pyrazolyl methanethione. Acta Pol. Pharm. Drug Res., 2007, 63, 435-439. (Pubitemid 351360399)
209. Ali, M. A.; Shaharyar, M.; Kumar, M.; Pandian, G. S. Synthesis and antitubercular activity of substituted novel pyrazoline derivatives. Nat Prod Res., 2007, 21, 575-579. (Pubitemid 47102966)
210. Martin, C. Tuberculosis vaccines: past, present and future. Curr. Opin. Pulm. Med., 2006, 12, 186-191. (Pubitemid 44350473)
211. Bonah, C. The experimental stable of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933. Stud. Hist. Philos. Biol. Biomed. Sci., 2005, 36, 696-721. (Pubitemid 43024789)
212. Ha, S.; Jeon, B.; Youn, J.; Kim, S.; Cho, S.; Sung, Y. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther., 2005, 12, 634-638. (Pubitemid 40468111)
213. Ibanga, H.; Brookes, R.; Hill, P.; Owiafe, P.; Fletcher, H.; Lienhardt, C.; Hill, A.; Adegbola, R.; McShane, H. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect. Dis., 2006, 6, 522-528. (Pubitemid 44160476)
214. Doherty, T. M.; Andersen, P. Vaccines for tuberculosis: Novel concepts and recent progress. Clin. Microbiol. Rev., 2005, 18, 687-702. (Pubitemid 41504511)
215. Dietrich, J.; Andersen, C.; Rappuoli, R.; Doherty, T. M.; Jensen, C. G.; Andersen, P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior Bacillus Calmette-Guerin immunity. J. Immunol., 2006, 177, 6353-6360. (Pubitemid 44628854)
216. Spigelman, M. K. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis., 2007, 196, 528-536.
217. O'Brien, R. Drug-resistant tuberculosis: etiology, management and prevention. Semin. Respir. Infect., 1994, 9, 104-112. (Pubitemid 24286908)
218. Castagnolo, D.; Radi, M.; Dessi, F.; Manetti, F.; Saddi, M.; Meleddu, R.; De Logu, A.; Botta, M. Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett., 2009, 19, 2203-2205.
219. Abdel-Rahman, H. M.; El-Koussi, N. A.; Hassan, H. Y. Fluorinated 1, 2, 4-Triazolo[1, 5-a]pyrimidine-6-carboxylic acid derivatives as antimycobacterial agents. Arch. Pharm., 2009, 342, 94-99.
220. Patel, N. B.; Khan, I. H.; Rajani, S. D. Pharmacological evaluation and characterizations of newly synthesized 1, 2, 4-triazoles. Eur. J. Med. Chem., 2010, 45, 4293-4299.
221. Gupte, A.; Boshoff, H. I.; Wilson, D. J.; Neres, J.; Labello, N. P.; Somu, R. V.; Xing, C.; Barry, C. E.; Aldrich, C. C. Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl) sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J. Med. Chem., 2008, 51, 7495-7507.
222. Kumar, S. G. V.; Rajendraprasad, Y.; Mallikarjuna, B. P.; Chandrashekar, S. M.; Kistayya, C. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1, 2, 4-triazole and 1, 3, 4-oxadiazoles as potential antimicrobial and antitubercular agents. Eur. J. Med. Chem., 2010, 45, 2063-2074.
223. Augustynowicz-Kopec, E.; Zwolska, Z.; Orzeszko, A.; Kazimierczuk, Z. Synthesis and antimycobacterial activity of selected nitrobenzyloxylated benzotriazoles. Acta Pol. Pharm. Drug Res., 2008, 65, 435-439.
224. Gill, C.; Jadhav, G.; Shaikh, M.; Kale, R.; Ghawalkar, A.; Nagargoje, D.; Shiradkar, M. Clubbed[1, 2, 3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. Bioorg. Med. Chem. Lett., 2008, 18, 6244-6247.
225. Singh, B. K.; Yadav, A. K.; Kumar, B.; Gaikwad, A.; Sinha, S. K.; Chaturvedi, V.; Tripathi, R. P. Preparation and reactions of sugar azides with alkynes: synthesis of sugar triazoles as antitubercular agents. Carbohydr. Res., 2008, 343, 1153-1162.
226. Joshi, S. D.; Vagdevi, H. M.; Vaidya, V. P.; Gadaginamath, G. S. Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems: a novel class of potential antibacterial and antitubercular agents. Eur. J. Med. Chem., 2008, 43, 1989-1996.
227. Ozdemir, A.; Turan-Zitouni, G.; Kaplancikli, Z. A.; Chevallet, P. Synthesis of some 4-arylidenamino-4H-1, 2, 4-triazole-3-thiols and their antituberculosis activity. J. Enzyme Inhib. Med. Chem., 2007, 22, 511-516. (Pubitemid 47225716)
228. Carta, A.; Palomba, M.; Paglietti, G.; Molicotti, P.; Paglietti, B.; Cannas, S.; Zanetti, S. [1, 2, 3]Triazolo[4, 5-H]quinolones: A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. Bioorg. Med. Chem. Lett., 2007, 17, 4791-4794. (Pubitemid 47187712)
229. Kucukguzel, I.; Kucukguzel, S. G.; Rollas, S.; Kiraz, M. Some 3-thioxo/alkylthio-1, 2, 4-triazoles with a substituted thiourea moiety as possible antimycobacterials. Bioorg. Med. Chem. Lett., 2001, 11, 1703-1707. (Pubitemid 32568302)
230. Kucukguzel, I.; Tatar, E.; Kucukguzel, S. G.; Rollas, S.; De Clercq, E. Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy) methyl]-4-alkyl/aryl-2, 4-dihydro-3H-1, 2, 4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur. J. Med. Chem., 2008, 43, 381-392. (Pubitemid 351215610)
231. Shiradkar, M.; Suresh Kumar, G. V.; Dasari, V.; Tatikonda, S.; Akula, K. C.; Shah, R. Clubbed triazoles: a novel approach to antitubercular drugs. Eur. J. Med. Chem., 2007, 42, 807-816. (Pubitemid 46810067)
232. Costa, M. S.; Boechat, N.; Rangel, E. A.; Da Silva, F. C.; De Souza, A. M.; Castro C. R.; Rodrigues, H. C.; Junior, I. N.; Lourenco, M. C.; Wardell, S. M.; Ferreira, V. F. Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1, 2, 3-triazole derivatives. Bioorg. Med. Chem., 2006, 14, 8644-8653. (Pubitemid 44679826)
233. Banfi, E.; Scialino, G.; Zampieri, D.; Mamolo, M. G.; Vio, L.; Ferrone, M.; Fermeglia, M.; Paneni, M. S.; Pricl, S. Antifungal and antimycobacterial activity of new imidazole and triazole derivatives-A combined experimental and computational approach. J. Antimicrob. Chemother., 2006, 58, 76-84. (Pubitemid 44294990)
234. Sanna, P.; Carta, A.; Nikookar, M. E. Synthesis and antitubercular activity of 3-aryl substituted-2-[1H (2H) benzotriazol-1 (2)-yl]acrylonitriles. Eur. J. Med. Chem., 2000, 35, 535-543. (Pubitemid 30395102)
235. Klimesova, V.; Zahajska, L.; Waisser, K.; Kaustova, J.; Mollmann, U. Synthesis and antimycobacterial activity of 1, 2, 4-triazole-3-benzylsulfanyl derivatives. Farmaco, 2004, 59, 279-288. (Pubitemid 38471921)
236. Zahajska, L.; Klimesova, V.; Koci, J.; Waisser, K.; Kaustova, J. Synthesis and antimycobacterial activity of pyridylmethylsulfanyl and naphthylmethylsulfanyl derivatives of benzazoles, 1, 2, 4-triazole, and pyridine-2-carbothioamide/-2-carbonitrile. Arch. Pharm., 2004, 337, 549-555. (Pubitemid 39486925)
237. Kaplancikli, Z. A.; Turan-Zitouni, G.; Chevallet, P. J. Synthesis and antituberculosis activity of new 3-alkylsulfanyl-1, 2, 4-triazole derivatives. J. Enzyme Inhib. Med. Chem., 2005, 20, 179-182. (Pubitemid 40645507)
238. Mendis, K.; Sina, B.; Marchesini, P.; Carter, R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg., 2001, 64, 97-106. (Pubitemid 32552576)
239. Bledsoe, G. H. Malaria primer for clinicians in the United States. Southern Medical Journal, 2005, 98, 1197-1204. (Pubitemid 43068354)
240. Lindsay, S.; Ansell, J.; Selman, C.; Cox, V.; Hamilton, K.; Walraven, G. Effect of pregnancy on exposure to malaria mosquitoes. Lancet, 2000, 355, 1972. (Pubitemid 30326107)
241. Van, G. J.; Thomas, F.; Erhart, A.; D'Alessandro, U. The contribution of malaria in pregnancy to perinatal mortality. Am. J. Trop. Med. Hyg., 2004, 71, 35-40. (Pubitemid 39121302)
242. Rodriguez-Morales, A. J.; Sanchez, E.; Vargas, M.; Piccolo, C.; Colina, R.; Arria, M.; Franco-Paredes, C. Pregnancy outcomes associated with Plasmodium vivax malaria in northeastern venezuela. Am. J. Trop. Med. Hyg., 2006, 74, 755-757. (Pubitemid 46774391)
243. Eckstein-Ludwig, U.; Webb, R.; Van Goethem, I.; East, J.; Lee, A.; Kimura, M.; O'Neill, P.; Bray, P.; Ward, S.; Krishna, S. Artemisinins target the SERCA of Plasmodium falciparum. Nature, 2003, 424, 957-961. (Pubitemid 37051688)
244. Uhlemann, A.; Cameron, A.; Eckstein-Ludwig, U.; Fischbarg, J.; Iserovich, P.; Zuniga, F.; East, M.; Lee, A.; Brady, L.; Haynes, R.; Krishna, S. A single amino acid residue may determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol., 2005, 12, 628-629. (Pubitemid 40980816)
245. Snow, R. W.; Guerra, C. A.; Noor, A. M.; Myint, H. Y.; Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 2005, 434, 214-217. (Pubitemid 40388051)
246. Mishra, N.; Arora, P.; Kumar, B.; Mishra, L. C.; Bhattacharya, A.; Awasthi, S. K.; Bhasin, V. K. Synthesis of novel substituted 1, 3-diaryl propenone derivatives and their antimalarial activity in vitro. Eur. J. Med. Chem., 2008, 43, 1530-1535. (Pubitemid 351885216)
247. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K. L.; Creason, S.; Shackleford, D. M.; Baldwin, J.; Charman, W. N.; Buckner, F. S.; Charman, S.; Rathod, P. K.; Phillips, M. A. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem., 2009, 52, 1864-1872.
248. Chen, Y.; Lopez-Sanchez, M.; Savoy, D. N.; Billadeau, D. D.; Dow, G. S.; Kozikowski, A. P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem., 2008, 51, 3437-3448. (Pubitemid 351875000)
249. Chan, D. C.; Laughton, C. A.; Queener, S. F.; Stevens, M. F. Structural studies on bioactive compounds Part 36: design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii. Bioorg. Med. Chem., 2002, 10, 3001-3010. (Pubitemid 34761880)
250. Havaldar, F. H.; Patil, A. R. Syntheses of 1, 2, 4 triazole derivatives and their biological activity. E-J. Chem., 2008, 5, 347-354.
251. Girmenia, C. New generation azole antifungals in clinical investigation. Expert. Opin. Investig. Drugs, 2009, 18, 1279-1295.
252. Elia, G.; Belloli, C.; Cirone, F. In vitro efficacy of ribavirin against canine distemper virus. Antiviral Res., 2008, 77, 108-113.
253. Bani-Sadr, F.; Carrat, F.; Pol, S. Risk factors for symptomatic mitochondrial toxicity in HIV/Hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J. Acquir. Immune Defic. Syndr., 2005, 40, 47-52. (Pubitemid 41233204)
254. Alvarez D., Dieterich D. T., Brau N., Moorehead L., Ball L., Sulkowski M. S. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J. Viral Hepat., 2006, 13, 683-689. (Pubitemid 44401197)
255. Crotty, S.; Cameron, C.; Andino, R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med., 2002, 80, 86-95. (Pubitemid 34169816)
256. Rachwalski, E. J.; Wieczorkiewicz, J. T.; Scheetz, M. H. Posaconazole: An oral triazole with an extended spectrum of activity. Ann. Pharmacother., 2008, 42, 1429-1438.
257. Cornely, O.; Maertens, J.; Winston, D.; Perfect, J.; Ullmann, A.; Walsh, T.; Helfgott, D.; Holowiecki, J.; Stockelberg, D.; Goh, Y.; Petrini, M.; Hardalo, C.; Suresh, R.; Angulo-Gonzalez, D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med., 2007, 356, 348-359. (Pubitemid 46148777)
258. Ullmann, A.; Lipton, J.; Vesole, D.; Chandrasekar, P.; Langston, A.; Tarantolo, S.; Greinix, H.; Morais de Azevedo, W.; Reddy, V.; Boparai, N.; Pedicone, L.; Patino, H.; Durrant, S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med., 2007, 356, 335-347. (Pubitemid 46148776)
259. Smith, J.; Safdar, N.; Knasinski, V.; Simmons, W.; Bhavnani, S.; Ambrose, P.; Andes, D. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother., 2006, 50, 1570-1572.